Researchers evaluate dental pulp cells as optimal source of iPS cells

NewsGuard 100/100 Score

Defined sets of factors can reprogram human cells to induced pluripotent stem (iPS) cells. However, many types of human cells are not easily accessible to minimally invasive procedures. In a paper published in the International and American Associations for Dental Research's Journal of Dental Research, lead researcher K. Tezuka and researchers N. Tamaoki, H. Aoki, T. Takeda-Kawaguchi, K. Iida, T. Kunisada and T. Shibata all from the Gifu University Graduate School of Medicine, Japan; and K. Takahashi, T. Tanaka and S. Yamanaka, all from Kyoto University, Japan, evaluate dental pulp cells as an optimal source of iPS cells, since they are easily obtained from extracted teeth and can be expanded under simple culture conditions.

From all six cell lines tested with the conventional three or four reprogramming factors, iPS cells were effectively established from five lines. Furthermore, determination of the HLA types of 107 DPC lines revealed two lines homozygous for all three HLA loci and showed that if an iPS bank is established from these initial pools, the bank will cover approximately 20 percent of the Japanese population with a perfect match.

Analysis of these data demonstrates the promising potential of dental pulp cell collections as a source of cell banks for use in regenerative medicine. Direct reprogramming of patients' somatic cells would allow for cell transplantation therapy free from immune-mediated rejection. An alternative approach is to establish an iPS cell bank consisting of various human leukocyte antigen (HLA) types. Safety issues must be considered as to which types of somatic cells should be used for such iPS cell banks.

"This work is significant in that it proposes the exciting potential of stem cell banking from readily available extracted teeth," said JDR Editor-in-Chief William Giannobile. "Although at an early stage of development, this innovation offers prospects for cell therapy approaches for the treatment of human disease."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients